ONCY

+ Watchlist + Portfolio

Oncolytics Biotech Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.83
52-Week Range: $0.73 – $1.51
Market Cap: $102.23M
P/E (TTM): —
EPS (TTM): -0.34
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -211.24%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.35
Debt/Equity: —
Total Debt: $448.00K
Free Cash Flow: $-12.01M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $98.56M

ONCY Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.37M	$13.35M	$15.44M	$13.31M
Selling, General & Admin	$8.18M	$11.82M	$10.10M	$15.41M
Operating Expenses	$19.84M	$25.47M	$25.54M	$28.73M
Operating Income	-$19.84M	-$25.47M	-$25.54M	-$28.73M
EBITDA	-$19.55M	-$25.17M	-$25.45M	-$28.66M
Pretax Income	-$18.24M	-$20.85M	-$22.70M	-$28.68M
Income Tax	$61.89K	$73.12K	$95.00K	$79.00K
Net Income	-$18.30M	-$20.92M	-$22.79M	-$28.76M
Diluted EPS	-0.32	-0.31	-0.29	-0.30
Diluted Shares	58.03M	67.62M	76.48M	95.86M

ONCY Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$8.60M	$26.32M	$11.08M	$5.20M
Receivables	$383.88K	$11.31K	$47.00K	$573.00K
Current Assets	$26.29M	$28.78M	$12.44M	$6.84M
Total Assets	$27.51M	$29.26M	$13.42M	$7.58M
Current Liabilities	$2.91M	$3.19M	$4.88M	$6.10M
Total Debt	$274.83K	$318.86K	$761.00K	$563.00K
Total Liabilities	$7.98M	$8.49M	$10.12M	$11.38M
Retained Earnings	-$308.17M	-$336.20M	-$400.74M	-$429.50M
Shareholders' Equity	$19.53M	$20.78M	$3.30M	-$3.80M
Working Capital	$23.39M	$25.58M	$7.55M	$743.00K

ONCY Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.21M	-$21.44M	-$19.88M	-$20.11M
Capital Expenditure	-$40.52K	-$6.03K	-$174.00K	-$6.00K
Free Cash Flow	-$17.25M	-$21.45M	-$20.06M	-$20.12M
Depreciation & Amortisation	$288.83K	$303.78K	$87.00K	$70.00K
Stock-Based Compensation	$1.75M	$1.56M	$1.98M	$3.10M
Investing Cash Flow	-$15.03M	$15.24M	-$174.00K	-$6.00K
Financing Cash Flow	$8.99M	$24.12M	$5.03M	$14.12M
Net Change in Cash	-$23.25M	$17.92M	-$15.03M	-$6.00M

ONCY Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.80M	$2.05M	$5.40M	$2.96M	$4.55M
Selling, General & Admin	$2.22M	$2.05M	$4.48M	$6.89M	$4.73M
Operating Expenses	$5.02M	$4.17M	$9.94M	$9.65M	$9.28M
Operating Income	-$5.02M	-$4.17M	-$9.94M	-$9.65M	-$9.28M
EBITDA	-$5.00M	-$4.05M	-$9.88M	-$9.65M	-$9.27M
Pretax Income	-$4.71M	-$4.44M	-$10.53M	-$8.98M	-$9.24M
Income Tax	—	$62.12K	-$181.07K	$198.99K	—
Net Income	-$4.71M	-$4.51M	-$10.35M	-$9.18M	-$9.24M
Diluted EPS	-0.06	-0.05	-0.10	—	-0.08
Diluted Shares	84.63M	91.00M	101.32M	—	112.29M

ONCY Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$10.69M	$10.69M	$8.88M	$5.20M	$5.49M
Receivables	$62.19K	$52.62K	$38.80K	$573.00K	$961.00K
Current Assets	$12.92M	$13.81M	$10.10M	$6.84M	$7.49M
Total Assets	$13.77M	$14.60M	$10.82M	$7.58M	$8.16M
Current Liabilities	$4.03M	$4.79M	$5.50M	$6.10M	$5.42M
Total Debt	$698.76K	$648.96K	$599.96K	$563.00K	$508.00K
Total Liabilities	$9.23M	$10.15M	$10.74M	$11.38M	$13.29M
Retained Earnings	-$338.48M	-$358.51M	-$362.83M	-$429.50M	-$438.74M
Shareholders' Equity	$4.54M	$4.45M	$82.63K	-$3.80M	-$5.13M
Working Capital	$8.89M	$9.02M	$4.60M	$743.00K	$2.06M

ONCY Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.73M	-$4.01M	-$4.63M	-$6.73M	-$7.29M
Capital Expenditure	-$1.00K	—	—	-$970.36	-$6.00K
Free Cash Flow	-$4.73M	-$4.01M	-$4.64M	-$6.73M	-$7.30M
Depreciation & Amortisation	$19.00K	$120.58K	$64.48K	-$134.06K	$16.00K
Stock-Based Compensation	$845.00K	$420.03K	$2.94M	-$1.10M	$2.30M
Investing Cash Flow	-$1.00K	$1.00K	-$5.03K	-$970.36	-$6.00K
Financing Cash Flow	$4.18M	$4.05M	$2.83M	$3.05M	$7.61M
Net Change in Cash	-$551.00K	$35.05K	-$1.80M	-$3.68M	$315.00K

Market Snapshot

About

Oncolytics Biotech Inc. is a Canadian clinical-stage biopharmaceutical company developing oncolytic viruses to treat cancer. Lead product uses viruses to selectively kill cancer cells while stimulating immune response.